CT1113 is a selective, orally active USP25/USP28 inhibitor. CT1113 inhibits cancer cell proliferation, induces apoptosis, and causes G2/S phase cell cycle arrest. CT1113 reduces the levels of total BCR-ABL1, phosphorylated BCR-ABL1, total STAT5, and phosphorylated STAT5, but does not alter the mRNA level of BCR-ABL1. CT1113 is applicable to research related to pancreatic cancer, colon cancer, and acute leukemia.[1][2]
Molecular Weight:
463.60
Purity:
99.61
CAS Number:
[2523435-18-7]
Formula:
C25H29N5O2S
Target:
Apoptosis,Bcr-Abl,c-Myc,Deubiquitinase,STAT
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
